

116TH CONGRESS  
1ST SESSION

# H. R. 2770

To waive the 24-month waiting period for Medicare eligibility for individuals disabled by Huntington's disease.

---

## IN THE HOUSE OF REPRESENTATIVES

MAY 15, 2019

Mr. PASCRELL (for himself, Mr. KINZINGER, Mr. LIPINSKI, Mr. SCHIFF, Ms. NORTON, Mr. COHEN, Ms. WASSERMAN SCHULTZ, Mr. LANGEVIN, Mr. PETERS, Mr. TONKO, Mr. FITZPATRICK, Ms. MCCOLLUM, Mrs. BEATTY, Mr. MASSIE, Mr. THOMPSON of Mississippi, Mr. MOULTON, Ms. DELBENE, Mr. FOSTER, Ms. CLARKE of New York, Mr. CICILLINE, Miss RICE of New York, Mr. YOUNG, Mr. KING of Iowa, Ms. BONAMICI, Mr. DEFazio, Mr. KILMER, Ms. DELAURO, Mr. HASTINGS, Mr. SERRANO, Mr. CONNOLLY, Mr. CLAY, Mr. DEUTCH, Mr. PRICE of North Carolina, Mr. ROGERS of Kentucky, Mr. WILSON of South Carolina, Mr. RODNEY DAVIS of Illinois, Mr. GOLDEN, Mr. MEEKS, Mr. MCGOVERN, Mr. GRIJALVA, Ms. PINGREE, Mr. KING of New York, Mr. HUNTER, Mr. GARAMENDI, Mr. COOPER, Ms. KAPTUR, Mr. AGUILAR, Mr. SMITH of New Jersey, Ms. HERRERA BEUTLER, Ms. KUSTER of New Hampshire, Mr. ZELDIN, Mrs. RADEWAGEN, Mr. HILL of Arkansas, Mr. POCAN, Mr. BEYER, and Mr. COOK) introduced the following bill; which was referred to the Committee on Ways and Means

---

## A BILL

To waive the 24-month waiting period for Medicare eligibility for individuals disabled by Huntington's disease.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2       This Act may be cited as the “Huntington’s Disease  
3 Parity Act of 2019”.

4 **SEC. 2. FINDINGS.**

5       Congress makes the following findings:

6           (1) Huntington’s disease is a progressive degen-  
7       erative neurological disease that causes total phys-  
8       ical and mental deterioration. In the United States,  
9       approximately 30,000 individuals are affected by  
10      Huntington’s disease, along with another 200,000  
11      individuals who are genetically “at risk”. There is no  
12      effective treatment in terms of halting or slowing the  
13      progression of the disease.

14          (2) Clinical indicators of Huntington’s disease  
15      include—

16           (A) loss of ability to control bodily move-  
17      ments;

18           (B) loss of ability to think or act quickly,  
19      inability to learn new material, and loss of  
20      memory; and

21           (C) behavioral or psychological problems,  
22      including personality changes, irritability, mood  
23      swings, anxiety, obsessive-compulsive behavior,  
24      inability to concentrate, decreased motivation,  
25      and severe depression.

1           (3) Adult-onset Huntington's disease typically  
2 results in the development of symptoms in individ-  
3 uals between 30 and 50 years of age. Late-onset  
4 Huntington's disease is characterized by develop-  
5 ment of symptoms after 50 years of age and is usu-  
6 ally associated with a milder course of the disease.  
7 Juvenile Huntington's disease affects individuals  
8 who have yet to attain 19 years of age and pro-  
9 gresses at a more rapid rate.

10          (4) Because of the incapacitating nature of  
11 Huntington's disease, individuals living with this ill-  
12 ness, including those in the early stages of the dis-  
13 ease, are unable to retain employment. As a result,  
14 many such individuals rely solely on Social Security  
15 Disability Insurance.

16          (5) After qualifying for Social Security Dis-  
17 ability Insurance, individuals with Huntington's dis-  
18 ease must wait another 24 months before receiving  
19 benefits under the Medicare program, despite the  
20 fact that such individuals often become incapacitated  
21 before reaching the age-eligibility requirement under  
22 the Medicare program of 65 years of age.

23          (6) In 2000, the Centers for Medicare & Med-  
24 icaid Services waived the 24-month waiting period  
25 requirement for people disabled by amyotrophic lat-

1       eral sclerosis (“ALS”), a degenerative neurological  
2       condition that is similar to Huntington’s disease.

3           (7) In light of the significant cognitive, behav-  
4       ioral, and physical incapacitation faced by individ-  
5       uals with this disease, there is an urgent need for  
6       the removal of the 24-month waiting period for cov-  
7       erage under the Medicare program for such individ-  
8       uals, similar to the existing exemption for individ-  
9       uals who have been diagnosed with ALS.

10 **SEC. 3. WAIVER OF 24-MONTH WAITING PERIOD FOR COV-**  
11 **ERAGE UNDER MEDICARE PROGRAM FOR IN-**  
12 **DIVIDUALS DIAGNOSED WITH HUNTINGTON’S**  
13 **DISEASE.**

14       (a) IN GENERAL.—Section 226(h) of the Social Secu-  
15       rity Act (42 U.S.C. 426(h)) is amended, in the matter pre-  
16       ceding paragraph (1), by inserting “or Huntington’s dis-  
17       ease (HD)” after “amyotrophic lateral sclerosis (ALS)”.

18       (b) EFFECTIVE DATE.—The amendment made by  
19       subsection (a) shall apply to benefits under title XVIII of  
20       the Social Security Act with respect to items and services  
21       furnished in months beginning after the date of the enact-  
22       ment of this Act.

○